Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults w...

Related Keywords

United States ,Rosalia Scampoli ,Katie Mcmanus ,Trevi Haduvio ,Exchange Commission ,Trademark Office ,Linkedin ,Prnewswire Trevi Therapeutics Inc ,Nasdaq ,Trevi Therapeutics Inc ,United States Patent ,Orange Book Listable ,Jennifer Good ,Chronic Cough ,Idiopathic Pulmonary ,Trevi Therapeutics ,Private Securities Litigation Reform Act ,